|
|
Volumn 372, Issue 9639, 2008, Pages 601-
|
|
Welcome clinical leadership at NICE
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
INTERFERON;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
BUDGET;
CANCER PATIENT;
COST EFFECTIVENESS ANALYSIS;
COST OF ILLNESS;
DISEASE SEVERITY;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
EDITORIAL;
GOVERNMENT;
HEALTH CARE POLICY;
HUMAN;
KIDNEY CARCINOMA;
PRIORITY JOURNAL;
PROGNOSIS;
QUALITY ADJUSTED LIFE YEAR;
SURVIVAL RATE;
TREATMENT RESPONSE;
UNITED KINGDOM;
UNSPECIFIED SIDE EFFECT;
|
|
EID: 49849096922
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(08)61249-0 Document Type: Editorial |
|
Times cited : (15)
|
|
References (0)
|